These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27602742)

  • 1. Pharmacogenetics: The right drug for you.
    Drew L
    Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
    [No Abstract]   [Full Text] [Related]  

  • 2. [PHARMACOGENOMICS AND PERSONALIZED MEDICINE: TOWARDS A SYSTEMATIC GENOMIC SCREENING?].
    Dideberg V; Segers K; Koopmansch B; Lambert F; Bours V
    Rev Med Liege; 2015; 70(5-6):251-6. PubMed ID: 26285448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.
    Alessandrini M; Chaudhry M; Dodgen TM; Pepper MS
    OMICS; 2016 Oct; 20(10):593-603. PubMed ID: 27643672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics: the path to individualised patient care.
    Adelung MR; Fitzsimons VM
    Br J Nurs; 2014 Jul 10-23; 23(13):738-9. PubMed ID: 25072336
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Phillips EJ
    Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics of drug hypersensitivity.
    Phillips EJ; Mallal SA
    Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine.
    Ramsey LB; Prows CA; Zhang K; Saldaña SN; Sorter MT; Pestian JP; Wenstrup RJ; Vinks AA; Glauser TA
    Clin Pharmacol Ther; 2019 Jan; 105(1):49-52. PubMed ID: 30058217
    [No Abstract]   [Full Text] [Related]  

  • 13. Preventing toxicity with a gene test.
    Marshall E
    Science; 2003 Oct; 302(5645):588-90. PubMed ID: 14576416
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
    Tonk ECM; Gurwitz D; Maitland-van der Zee AH; Janssens ACJW
    Pharmacogenomics J; 2017 Jul; 17(4):386-392. PubMed ID: 27168098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 18. Abacavir hypersensitivity.
    Vandekerckhove L; Blot S; Vogelaers D
    N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
    Ingelman-Sundberg M
    N Engl J Med; 2008 Feb; 358(6):637-9. PubMed ID: 18256400
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.